The IVL- ELCA DRAGON Registry is a multicenter study that enrolled consecutive patients with stent underexpansion treated with IVL ora ELCA in high-volume PCI centers. The primary efficacy endpoint was device success (technical success with a final stent expansion ≥ 80%). Thirty days device-oriented composite endpoint (DOCE: cardiac death, target lesion revascularization, or target vessel myocardial infarction) was the secondary endpoint.
Study Type
OBSERVATIONAL
Enrollment
121
Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.
Unit of Structural Interventional Cardiology, Department of Clinical and Experimental Medicine, Careggi University Hospital
Florence, Italy
Fabrizio D'Ascenzo
Turin, Italy
Department of Invasive Cardiology, Medical University of Bialystok, The Medical University of Bialystok Clinical Hospital
Bialystok, Poland
First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland
Gdansk, Poland
Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
Katowice, Poland
Jacek Legutko
Krakow, Poland
Second Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
Krakow, Poland
1st Military Hospital in Lublin, Lublin, Poland
Lubin, Poland
Department of Cardiology, Copper Health Centre (MCZ)
Lubin, Poland
Clinical Department of Interventional Cardiology, Medical University of Lublin
Lublin, Poland
...and 10 more locations
The primary efficacy endpoint was device success
Technical success with a final stent expansion ≥80%.
Time frame: During procedure
Device-oriented composite endpoint (DOCE)
cardiac death, target lesion revascularization, or target vessel myocardial infarction
Time frame: Thirty days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.